For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Ligand Pharmaceuticals, Inc.

USPTO Granted Patents = 134

CIPO Patents = 20

EPO Patents = 11

Trademarks = 13

Forward Citations = 1,543

Loading Chart...

Loading Chart...

201 inventors (with patents filed for the assignee):

Lin Zhi (75 out of 126 patents)

Todd Kevin Jones (27 out of 110 patents)

James Patrick Edwards (23 out of 165 patents)

4. Cornelis Arjan Van Oeveren (22 out of 22 patents)

5. Marcus F Boehm (18 out of 64 patents)

6. Richard Alan Heyman (16 out of 24 patents)

7. Yixing Shen (15 out of 15 patents)

8. Bijan Pedram (15 out of 18 patents)

9. Christopher Michael Tegley (15 out of 89 patents)

10. Lawrence G Hamann (12 out of 65 patents)

11. Jason Conrad Pickens (12 out of 15 patents)

12. Robert Higuchi (10 out of 20 patents)

13. David T Winn (10 out of 21 patents)

14. Luc J Farmer (9 out of 57 patents)

15. Sarah J West (9 out of 9 patents)

Core Competencies:

Topical Antiviral Compositions

Crystalline Forms

Glucagon Receptor Antagonists

Acetal Compounds

Imidazo-Fused Heterocycles

Selective Androgen Receptor Modulators

Nucleotide Prodrug Compounds

Granulocyte Colony-Stimulating Factor Receptor

Hematopoietic Growth Factor Mimetic Compounds

Androgen Receptor Modulators

Heterocycle Amines

Biaryl Oxyacetic Acid Compounds

134 patents: Sort by Forward Citations

1. 12403087 - Topical antiviral compositions, delivery systems, and methods of using the same (2025-09-02),

2. 12319651 - Crystalline forms and methods of producing crystalline forms of a compound (2025-06-03),

3. 12208071 - Glucagon receptor antagonists (2025-01-28),

4. 11970482 - Acetal compounds and therapeutic uses thereof (2024-04-30),

5. 11858938 - Imidazo-fused heterocycles and uses thereof (2024-01-02),

6. 11773110 - Heterocycle amines and uses thereof (2023-10-03),

7. 11566041 - Nucleotide prodrug compounds (2023-01-31),

8. 11413274 - Methods and compositions associated with the granulocyte colony-stimulating factor receptor (2022-08-16),

9. 11358931 - Selective androgen receptor modulators (SARMs) and uses thereof (2022-06-14),

10. 11278559 - Prodrug compounds and their uses (2022-03-22),

11. 11186593 - Heterocycle amines and uses thereof (2021-11-30),

12. 10874638 - Methods and compositions for modulating hormone levels (2020-12-29),

13. 10807983 - Imidazo-fused heterocycles and uses thereof (2020-10-20),

14. 10736875 - Methods and compositions associated with the granulocyte colony-stimulating factor receptor (2020-08-11),

15. 10730831 - Selective androgen receptor modulators (SARMs) and uses thereof (2020-08-04),

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of medicines to address unmet medical needs. They partner with pharmaceutical companies around the world to develop innovative therapies in various therapeutic areas. Through their proprietary technology platforms, they provide expertise in drug discovery, development, and commercialization. With a diverse portfolio of programs, Ligand aims to improve patient outcomes and enhance the value of its partnerships.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

134 Patents

#42 in San Diego, CA

#646 in California

#2,780 in US

#5,841 in the World

San Diego, CA, United States of America

Ligand Pharmaceuticals, Inc.

Forward Citations = 1,543

201 inventors:

Lin Zhi (75 out of 126 patents)

Todd Kevin Jones (27 out of 110 patents)

James Patrick Edwards (23 out of 165 patents)

4. Cornelis Arjan Van Oeveren (22 out of 22 patents)

5. Marcus F Boehm (18 out of 64 patents)

Please report any incorrect information to support@idiyas.com

Loading…